ExelixisEXEL
EXEL
About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees: 1,147
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
166% more first-time investments, than exits
New positions opened: 117 | Existing positions closed: 44
31% more capital invested
Capital invested by funds: $6.37B [Q3] → $8.33B (+$1.96B) [Q4]
29% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 9 (+2) [Q4]
18% more call options, than puts
Call options by funds: $58.6M | Put options by funds: $49.7M
15% more funds holding
Funds holding: 447 [Q3] → 512 (+65) [Q4]
1.47% more ownership
Funds ownership: 86.06% [Q3] → 87.53% (+1.47%) [Q4]
4% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 165
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$29
21%
downside
Avg. target
$38
2%
upside
High target
$45
22%
upside
10 analyst ratings
6 positive
60%
4 neutral
40%
0 negative
0%
JMP Securities Silvan Tuerkcan 20% 1-year accuracy 10 / 51 met price target | 11%upside $41 | Market Outperform Reiterated | 17 Apr 2025 |
HC Wainwright & Co. Robert Burns 17% 1-year accuracy 29 / 167 met price target | 9%upside $40 | Buy Reiterated | 27 Mar 2025 |
RBC Capital Gregory Renza 19% 1-year accuracy 15 / 78 met price target | 9%upside $40 | Outperform Maintained | 13 Mar 2025 |
Wells Fargo Derek Archila 48% 1-year accuracy 14 / 29 met price target | 2%downside $36 | Equal-Weight Downgraded | 24 Feb 2025 |
Barclays Peter Lawson 4% 1-year accuracy 1 / 24 met price target | 21%downside $29 | Equal-Weight Maintained | 13 Feb 2025 |
Financial journalist opinion
Based on 10 articles about EXEL published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Exelixis (EXEL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Neutral
Business Wire
4 days ago
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities 2025 Health Care Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 14 in Las Vegas. RBC Capital Markets 2025 Global Healthcare Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Tuesday, May 20 in New York City. To access th.
Positive
Zacks Investment Research
1 week ago
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
Business Wire
1 week ago
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon regis.
Neutral
GlobeNewsWire
1 week ago
EXEL Industries: Second quarter 2024–2025 sales down 3.8%
Q2 2024–2025 revenue: -3.8% Businesses proved to be resilient in an uncertain economic context Q2 sales (January 2025–March 2025)) 2023–2024 2024–2025 Change (reported) Change (LFL*) Reported Reported €m % €m % AGRICULTURAL SPRAYING 157.4 132.7 -24.7 -15.7% -25.2 -16.0% SUGAR BEET HARVESTING 17.1 25.3 +8.1 +47.6% +9.4 +54.7% LEISURE 47.4 47.3 -0.0 -0.1% -0.4 -0.8% INDUSTRY 70.7 76.0 +5.3 +7.5% +3.7 +5.2% EXEL Industries Group 292.6 281.4 -11.3 -3.8% -12.6 -4.3% Like-for-like (LFL) = at constant consolidation scope and foreign exchange rates 6-month sales (October 2024–March 2025)) 2023–2024 2024–2025 Change (reported) Change (LFL*) Reported Reported €m % €m % AGRICULTURAL SPRAYING 248.3 194.9 -53.4 -21.5% -53.7 -21.6% SUGAR BEET HARVESTING 44.2 44.4 +0.2 +0.4% +1.1 +2.6% LEISURE 58.5 60.2 +1.8 +3.0% -0.5 -0.8% INDUSTRY 141.7 143.9 +2.2 +1.5% +1.8 +1.3% EXEL Industries Group 492.7 443.4 -49.4 -10.0% -51.3 -10.4% Like-for-like (LFL) = at constant consolidation scope and foreign exchange rates Q2 revenue 2024-2025 The EXEL Industries Group generated revenue of €281.4 million in the second quarter of the 2024-2025 fiscal year, down -3.8% on the previous year, mainly due to lower volumes in Agricultural Spraying, with other activities either stable or growing. At constant scope and foreign exchange rates, revenue was down -4.3%.
Positive
Investors Business Daily
2 weeks ago
MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
Stocks near buy points include Charles Schwab, German software leader SAP and MercadoLibre, the so-called Amazon of Latin America,
Neutral
Zacks Investment Research
2 weeks ago
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
Positive
Zacks Investment Research
2 weeks ago
Here's Why Exelixis (EXEL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
2 weeks ago
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
3 weeks ago
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Charts implemented using Lightweight Charts™